Sugi Predict

Sugi Predict / Compounds / SCHEMBL2448494

SCHEMBL2448494

SCHEMBL2448494

CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OCc2ccccc2)C[C@H]1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 2/20 0.56
▸ PDE4B Q07343 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ HTT P42858 1/20 0.49
▸ CYP2C19 P33261 1/20 0.48
▸ CTSL P07711 1/20 0.46
▸ KMT2A Q03164 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HSD11B1 P28845 1/20 0.45
▸ GRIN2B Q13224 3/20 0.44
▸ CYP2D6 P10635 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ GPR119 Q8TDV5 1/20 0.44
▸ STS P08842 1/20 0.44
▸ SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27440737 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL3218744 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL376621 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL3218733 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL3218754 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL14131844 0.94 PDE4B (0.54) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL4791190 0.94 PDE4B (0.54) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL14145058 0.94 PDE4B (0.54) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL2348338 0.92 CTSK (0.58) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL16841174 0.92 PDE4B (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667056-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-12-24 — — EP disclosed
EP-4452415-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-30 — — EP disclosed
US-12122764-B2 IKAROS zinc finger family degraders and uses thereof GILEAD SCIENCES, INC. (US) 2024-10-22 — — US disclosed
CN-118488948-A IKAROS zinc finger family degradation agent and application thereof 吉利德科学公司 2024-08-13 — — CN disclosed
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-08-03 — — US disclosed
WO-2023122615-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-06-29 — — WO disclosed
EP-3298003-B1 BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2023-04-19 — — EP disclosed
US-20230002408-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2023-01-05 — — US disclosed
EP-4077305-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS Janssen Pharmaceutica NV (BE) 2022-10-26 — — EP disclosed
CN-114867717-A Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection 詹森药业有限公司 2022-08-05 — — CN disclosed
WO-2010058032-A2 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 — — WO disclosed
EP-1699797-B1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-09-23 — — EP disclosed
EP-2058314-A1 Pyrrolotriazine compounds as kinase inhibitors Bristol-Myers Squibb Company (US) 2009-05-13 — — EP disclosed
WO-2008106692-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-04 — — WO disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 — — US disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 — — US disclosed
EP-1578743-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2006-11-29 — — EP disclosed
US-20060041123-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2006-02-23 — — US disclosed
EP-1578743-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2005-09-28 — — EP disclosed
WO-2004058144-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2004-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF IKZF2, IKZF1, IKZF3 CTSK 471/4885PDE4B 4751/4885SMN1; SMN2 2059/4885
US-12122764-B2 IKAROS zinc finger family degraders and uses thereof IKZF2, IKZF1, IKZF3 CTSK 1880/4885PDE4B 4830/4885SMN1; SMN2 1689/4885
US-20060041123-A1 Antibacterial agents NQO2, NRDC, IFNG CTSK 822/4885PDE4B 1435/4885SMN1; SMN2 2706/4885
US-20230002408-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HAVCR2, HCCS, PYGL CTSK 3312/4885PDE4B 2052/4885SMN1; SMN2 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.